Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Eli Lilly's Zepbound Surges to 10th in Trading Volume Ranking with 66.57 Billion in Volume and 2.86% Stock Price Increase

Market BriefMonday, May 12, 2025 8:49 pm ET

1min read

On May 12, 2025, Eli Lilly's trading volume reached 66.57 billion, marking an 119.18% increase from the previous day, placing it at the 10th position in the day's stock market rankings. Meanwhile, Eli Lilly's stock price rose by 2.86%.

Eli Lilly's Zepbound has shown superior weight loss results compared to Novo Nordisk's Wegovy in a head-to-head study. Participants using Zepbound achieved an average weight loss of 20.2% over 72 weeks, compared to 13.7% with Wegovy. This study, published in The New England Journal of Medicine, highlights Zepbound's effectiveness in reducing body weight and waist circumference, which is a critical metric for assessing health risks associated with abdominal fat.

Zepbound's dual-target approach, which mimics two gut hormones, has been found to enhance treatment effectiveness. The study involved around 750 obese patients without diabetes, who were asked to take the highest dose they could tolerate of either Zepbound or Wegovy. The results showed that more patients treated with Zepbound achieved significant reductions in body weight and waist circumference compared to those on Wegovy.

Novo Nordisk, however, has disputed the findings, stating that their own studies and real-world evidence show consistent results of a 17% weight loss with Wegovy. The Danish company also noted that the Lilly trial used higher doses of Zepbound compared to Wegovy, which could account for the differences in outcomes.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.